Saturday, October 3, 2026

USD/CNH Bearish Momentum: 0.93% Down In The Last 10 Sessions

ViaNews Editorial Team

September 24, 2023

USD/CNH Bearish Momentum: 0.93% Down In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 0.93% for the last 10 sessions. At 16:06 EST on Sunday, 24 September, USD/CNH (USDCNH) is $7.29.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0.003% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CNH's Forex is considered to be oversold (<=20).

News about

  • Eur/usd remains under selling pressure near 1.0650, investors await eurozone, US PMI. According to FXStreet on Friday, 22 September, "This, in turn, boosts the Greenback and acts as a headwind for the EUR/USD pair. ", "Traders will take cues from these figures and find trading opportunities around the EUR/USD pair."
  • Eur/usd treading water near 1.0660, hanging near the top of the range. According to FXStreet on Friday, 22 September, "Hourly candles see the EUR/USD trading just south of the 200-hour Simple Moving Average (SMA) near 1.0685.", "The EUR/USD is trading into neutral ground heading into the end of the trading week, testing well-trodded ground near the 1.0660 handle."
  • Eur/usd forecast: faces challenging times amidst consolidation and US dollar strength - 22 September 2023. According to DailyForex on Friday, 22 September, "In this environment, the Euro is expected to continue facing difficulties, although short-term rallies may provide opportunities to acquire "cheap US dollars." A decisive break below the session's low on Thursday could potentially pave the way for the EUR/USD pair to descend towards the 1.05 level. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com